Dbv Technologies SA

DBVT · NYSE

$9.75+$0.07 (+0.72%)TodayMarket closed ·
Prev close $9.68

Latest news

  • Press releaseGlobe Newswire

    DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

  • Press releaseGlobe Newswire

    DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales

  • Press releaseGlobe Newswire

    DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update

  • Press releaseGlobe Newswire

    DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

  • Press releaseGlobe Newswire

    DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index

  • Press releaseGlobe Newswire

    DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

  • Press releaseGlobe Newswire

    DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

  • Press releaseGlobe Newswire

    Combined General Meeting of June 3, 2026

  • Press releaseGlobe Newswire

    DBV Technologies Reports First Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    DBV Technologies Reports Full Year 2025 Financial Results and Business Update

  • NewsAvi Kapoor

    Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • NewsAvi Kapoor

    Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • NewsNamrata Sen

    How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

  • NewsGianni di Poce

    The Insider Report: A Tape Fitting for the Holiday

  • NewsAvi Kapoor

    Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • NewsAvi Kapoor

    Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

  • NewsAvi Kapoor

    Why MillerKnoll Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    Crude Oil Rises Over 1%; General Mills Earnings Top Views

  • NewsAvi Kapoor

    Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday

  • NewsVandana Singh

    Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

  • NewsAvi Kapoor

    Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • NewsAvi Kapoor

    PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • NewsHenry Khederian

    Why DBV Technologies (DBVT) Stock Is Skyrocketing

  • NewsRishabh Mishra

    US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'

  • Press releaseGlobe Newswire

    DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

  • News

    Market-Moving News for December 12th

  • NewsAvi Kapoor

    Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • NewsVandana Singh

    Penny Stock DBV Technologies Advances Viaskin Peanut Allergy Patch With FDA Approval Pathway

  • NewsAvi Kapoor

    Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.